Advance of drug metabolism enzyme P450 2C9

Abstract

Abstract: P450 2C9 is the most important drug metabolizing enzymes in humans.Polymorphisms in P450 2C9 gene produce variants at amino acid including P450 2C9 *2 and P450 2C9 *3.Metabolic capacities for P450 2C9 substrates are diminished by individuals of homozygous.P450 2C9 substrates mainly include tolbutamide, phenytoin, S-warfarin, fluoxetine, and losartan.P450 2C9 can be induced by rifampin and inhibited by amiodarone and fluconazole.

Key words: P450 2C9, genetic polymorphism, drug metabolism, pharmacogenetics

CLC Number:

R969

CHEN Kun, WANG Rui. Advance of drug metabolism enzyme P450 2C9[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(6): 601-606.

References

1 Lee S, Kim JM, Chung CS, Cho KJ, Kim JH.Polymorphism in CYP2C9 as a non-critical factor of warfarin dosage adjustment in Korean patients[J].Arch Pharm Res, 2003;26(11):967-72
2 Schwarz UI.Clinical relevance of genetic polymorphisms in the human CYP2C9 gene[J].Eur J Clin Invest, 2003;33(2):23-30
3 Bozina N, Granic P, Lalic Z, Tramisak I, Lovric M, Stavljenic RA.Genetic polymorphisms of cytochromes P450:CYP2C9, CYP2C19, and CYP2D6 in Croatian population[J].Croat Med J, 2003;44(4):425-8
4 Yang JQ, Morin S, Verstuyft C, Fan LA, Zhang Y, Xu CD, et al.Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations[J].Fundam Clin Pharmacol, 2003;17(3):373-6
5 Takahashi H, WilkinsonGR, Caraco Y, Muszkat M, Kim RB, Kashima T, et al.Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients[J].Clin Pharmacol Ther, 2003;73(3):253-63
6 Xie HG, Prasad HC, Kim RB,Stein CM.CYP2C9 allelic variants:ethnic distribution and functional significance[J].Adv Drug Deliv Rev, 2002;54(10):1257-70
7 Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP, Shimada T.Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian Populations[J].Pharmacogenetics, 1997;7(2):103-113
8 Kidd RS, Straughn AB, Meyer MC, Blaisdell J, Goldstein JA, Dalton JT.Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and in an individual homozygous for the CYP2C9 ＊3 allele[J].Pharmacogenetics, 1999:9(1):71-80
9 Van der Weide J, Steijns LS, van Weelden MJ, de Haan K. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement[J].Pharmacogenetics, 2001;11(4):287-91
10 Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R.Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance[J].Clin Pharmacol Ther, 2002;72(6):702-10
11 Yoon YR, Shon JH, Kim MK, Lim YC, Lee HR, Park JY, et al.Frequency of cytochrome P450 2C9 mutant alleles in a Korean population[J].Br J Clin Pharmacol, 2001;51(3):277-80
12 Aithal GP, Day CP, Kesteven PJ, Daly AK.Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications[J].Lancet, 1999;353(9154):717-9
13 Lee CR, Pieper JA, Hinderliter AL, Blaisdell JA, Goldstein JA.Evaluation of cytochrome P450 2C9 metabolic activity with tolbutamide in CYP2C9 heterozygotes [J].Clin Pharmacol Ther, 2002;72(5):562-71
14 Miners JO, Birkett DJ.Cytochrome P450 2C9:an enzyme of major importance in human drug metabolism[J].Br J Clin Pharmacol, 1998;45(6):525-38
15 McCrea JB, Cribb A, Rushmore T, Osborne B, Gillen L, Lo MW, et al.Phenotypic and genotypicinvestigations of a healthy volunteer deficient in the conversion oflosartan to its active metabolite E-3174[J].Clin Pharmacol Ther, 1999;65(3):348-52
16 卢爱华, 舒焱, 周宏灏.细胞色素氧化酶CYP2C9 的研究进展[J].中国临床药理学杂志, 2000;16(5):381-85
17 Miners JO, Coulter S, Birkett DJ, Goldstein JA.Torsemidemetabolism by CYP2C9 variants and Other human CYP2C subfamily enzymes[J].Pharmacogenetics, 2000;10(3):267-70
18 Huang SI, Hiratsuka M.Allele and genotype frequencies of polymophic Cytochromes P450 (2C9, 2C19, 2E1)and dihydropynmidine dehydrogenase (DPYD) in the Egyptian population [J].Br J Clin Pharmacol, 2002;53(6):596-603

[1]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[2]	ZHANG Yuanjin, HUANG Shengbo, LIU Jie, WANG Xin. Construction and application of innovation gene-edited rats and intestinal 3D organoids models in drug metabolism and pharmacokinetics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 914-922.
[3]	LIN Rongfang, ZHENG Weiwei, LIU Yiwei, LIN Cuihong, WANG Changlian, HUANG Pinfang. Correlation of infliximab related genetic polymorphism, serum trough concentration and efficacy in patients with Crohn's disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1000-1006.
[4]	LI Ling, ZHAO Huijia, CHEN Binyao, LIU Xiaohong, SUN Gongpeng, HAO Zhuowen, FAN Zhipeng, YUE Jiang, WU Jianguo, YE Qifa. Relevance of CYP2R1 genetic polymorphism and individual therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1053-1059.
[5]	CHEN Hongzhu, LIU Jianming, ZHOU Fang, JIA Yuanwei, WANG Guangji, ZHANG Jingwei. Effect and mechanism of endogenous metabolism on drug metabolism and disposition [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 580-588.
[6]	XIE Shangchen, LI Wei, LIAO Ping, HE Yijing, MCLEOD Howard L.. Research progress of general anesthesia in the pharmacogenetics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 217-222.
[7]	CHEN Binyao, LI Ling, ZHAO Huijia, LIU Xiaohong, QI Zhenhua, SUN Gongpeng, HAO Zhuowen, FAN Zhipeng, DONG Li, YUE Jiang, YE Qifa. Relevance of CYP1B1 genetic polymorphism and individual therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(11): 1309-1316.
[8]	ZHOU Yuan, LU Xueling, ZHAO Jun, ZHANG Li, YANG Huanjie，WANG Ning. Polymorphism distribution of rs316019 of SLC22A2 in the Uygur population of Xinjiang [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(3): 287-293.
[9]	LIN Xiuxian, CHEN Dan, ZHAO Qing, CHEN Yao. Genetic research on the incidence of alcoholic liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(11): 1309-1314.
[10]	HU Jing, ZHU Jun-rong, YU Feng. Efficacy and safety of warfarin dosage algorithms in clinical application:A Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(3): 296-303.
[11]	MA Xiao-qin, XIN Hua-wen, LI Yuan-qi, HUANG Hui, ZHAO Li, YU Ai-rong, LI Wei-liang, WU Xiao-chun. Association of HGPRT activity and gene polymorphism with adverse reactions caused by azathioprine in kidney transplant recipients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(2): 182-187.
[12]	ZHENG Yi, YIN Ji-ye, ZHOU Hong-hao, LIU Zhao-qian. Advances in relationship of genetic polymorphism with the toxicity caused by platinum-based therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(9): 1051-1056.
[13]	WU Ji-chu, OUYANG Ze-wei, LUO Can-xiang. Effect of ABCG2 genetic polymorphism on atorvastatin modifying serum lipids [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(8): 882-884.
[14]	OUYANG Cang-hong, XIE Juan. Study on the relationship between the MDR1 and CYP3A genetic polymorphisms and serum digoxin concentration in 111 patients with chronic heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(3): 291-296.
[15]	LI Mu-peng, XIONG Yan, CHEN Xiao-ping. Progress in pharmacokinetics, pharmacodynamics and pharmacogenetics of the antiplatelet drug ticagrelor [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(2): 214-222.